18:30 , Jul 12, 2018 |  BC Extra  |  Financial News

Assembly raises $144M follow-on

Assembly Biosciences Inc. (NASDAQ:ASMB) raised $144 million late Wednesday through the sale of 4 million shares at $36 in a follow-on underwritten by Jefferies, Leerink, William Blair, Mizuho Securities, Baird and National Securities Corp. The...
00:05 , May 20, 2017 |  BioCentury  |  Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
17:22 , May 15, 2017 |  BC Extra  |  Company News

Orphan drug giant Termeer passes away

Henri Termeer, the former chairman, president and CEO of Genzyme Corp. and one of the handful of individuals who personified the biotech industry in its early decades, passed away May 12 at age 71. Termeer...
22:17 , Jan 12, 2017 |  BC Week In Review  |  Company News

Lysosomal, Allergan deal

Allergan purchased from Lysosomal an exclusive option to acquire the company following completion of a Phase Ib trial of LTI-291. The preclinical candidate is designed to simulate activity of glucocerebrosidase (GBA; GCase) in the brain...
00:30 , Jan 10, 2017 |  BC Extra  |  Company News

Allergan in deals with Lysosomal Therapeutics, Assembly

Allergan plc (NYSE:AGN) announced two deals Monday, gaining an exclusive option to acquire neurodegenerative disease company Lysosomal Therapeutics Inc. (Cambridge, Mass.) and a license for rights to four gastrointestinal microbiome programs from Assembly BioSciences Inc....
08:00 , Feb 9, 2015 |  BC Week In Review  |  Financial News

Lysosomal Therapeutics completes venture financing

Lysosomal Therapeutics Inc. , Cambridge, Mass.   Business: Neurology   Date completed: 2015-02-03   Type: Venture financing   Raised: $20 million   Investors: Atlas Venture; Hatteras Venture Partners; Lilly Ventures; Sanofi-Genzyme BioVentures; Roche Venture Fund;...
02:55 , Feb 4, 2015 |  BC Extra  |  Financial News

Insiders back Lysosomal in $20M A round

Lysosomal Therapeutics Inc. (Cambridge, Mass.) raised $20 million in a series A round from existing investors including Atlas Venture; Hatteras Venture Partners; Lilly Ventures; Sanofi-Genzyme BioVentures; Roche Venture Fund; Partners Innovation Fund; Orion Equity Partners;...
07:00 , May 26, 2014 |  BioCentury  |  Emerging Company Profile

Lysosomal: Activating GCase

Lysosomal Therapeutics Inc. is developing brain-penetrant small molecules for a genetically validated Parkinson's target that it believes will be disease-modifying for idiopathic PD and potentially other synucleinopathies. The biotech has a license from NIH to...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Lysosomal Therapeutics board of directors update

Lysosomal Therapeutics Inc. , Cambridge, Mass.   Business: Neurology   Appointed: Bruce Booth, partner at Atlas Venture; Bernard Davitian, VP and managing director at Sanofi-Genzyme BioVentures; Steve Hall, venture partner at Lilly Ventures; Carole Nuechterlein,...
07:00 , May 19, 2014 |  BC Week In Review  |  Financial News

Lysosomal Therapeutics completes venture financing

Lysosomal Therapeutics Inc. , Cambridge, Mass.   Business: Neurology   Date completed: 5/12/14   Type: Venture financing   Raised: $4.8 million   Investors: Atlas Ventures; Hatteras Venture Partners; Lilly Ventures; Sanofi-Genzyme BioVentures; Roche Venture Fund;...